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Summary 
Three commercially available pharmacophore generation programs, Catalyst/HipHop, 
DISCO and GASP, were compared on their ability to generate known pharmacophores 
deduced from protein-ligand complexes extracted from the Protein Data Bank. Five different 
protein families were included Thrombin, Cyclin Dependent Kinase 2, Dihydrofolate 
Reductase, HIV Reverse Transcriptase and Thermolysin. Target pharmacophores were 
defined through visual analysis of the data sets. The pharmacophore models produced were 
evaluated qualitatively through visual inspection and according to their ability to generate the 
target pharmacophores. Our results show that GASP and Catalyst outperformed DISCO at 
reproducing the five target pharmacophores. 
Introduction 
A pharmacophore is the spatial arrangement of key chemical features that are recognised by a 
receptor and are thus responsible for ligand-receptor binding [1]. Pharmacophore models are 
typically used when some active compounds have been identified but the three-dimensional 
(3D) structure of the target protein or receptor is unknown. The active compounds are 
superimposed to determine their common features and hence to provide a pharmacophore 
model that explains ligand-receptor binding. Once such a model has been derived it can be 
used to: search for other molecules that contain the same pharmacophore and that may also 
be active; to explain structure activity relationships within a series of molecules; and to form 
a basis for the design of new potentially active molecules. 
                                                 
* Author to whom correspondence should be addressed. 
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Given a set of active molecules, the identification of a pharmacophore involves two steps: 
analysing the molecules to identify pharmacophoric features, that is, atoms that can interact 
with a receptor, and aligning the active conformations of the molecules to find the best 
overlay of the corresponding features. The main difficulty in pharmacophore generation is in 
the handling conformational flexibility since the active conformations of the molecules are 
usually unknown. 
Several programs have been developed for the automatic identification of pharmacophore 
models [2]. The main differences between the programs lie in the algorithms used for the 
alignment and in the way in which conformational flexibility is handled. Here, three 
commercially available programs DISCO, Catalyst/HipHop and GASP are compared with 
regard to their ability to reproduce known pharmacophores which have been determined by 
analysing crystallographic data for a series of ligands bound to the same protein. 
The main features of the programs are given in the next section which is then followed by a 
description of the methodology and the datasets used in the study. Finally the results are 
presented and conclusions drawn. 
The Programs 
In DISCO [3, 4], each molecule is characterised by ligand points and site points. Ligand 
points include atoms with positive charge, negative charge, hydrogen bond donor, hydrogen 
bond acceptor and hydrophobic character. Site points represent the hypothetical position of 
complementary atoms in a receptor and are determined from the position of heavy atoms in 
the ligand structure. Conformational flexibility is handled by precomputing a series of low 
energy conformers for each molecule with each conformer being treated as a rigid body 
during the alignment step. A conformer is represented by the interpoint distances calculated 
for the ligand and site points and a clique detection algorithm is used to align structures based 
on these distances. The Bron-Kerbosh clique-detection algorithm has been modified to allow 
multiple alternative conformations of molecules to be considered and to preserve chirality of 
molecules.  
The molecule with the fewest conformations is used as a reference molecule. DISCO 
compares each conformation of the reference molecule in turn against all conformations of 
the other molecules. The cliques identified are examined to attempt to find a clique that is 
common to at least one conformation of every molecule. This process is repeated for every 
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conformation of the reference molecule. If no solution is found the tolerances on the clique 
detection process are increased until either a solution is found or the maximum tolerance is 
reached. Every molecule must contain all features of the pharmacophore, however, DISCO 
has the option of finding solutions where some molecules are excluded from the model. The 
output from a DISCO run is a ranked list of all possible pharmacophore mappings. 
Catalyst comprises two modules: HipHop and HypoGen [5]. HipHop attempts to derive a 
pharmacophore based on features that are common to active molecules whereas HypoGen 
makes use of quantitative activity data to derive the pharmacophore. This study uses the 
program HipHop [6]. The pharmacophoric features identified in HipHop are hydrogen bond 
donors and acceptors, negative and positive charge centres, and surface accessible 
hydrophobic regions [7]. As in DISCO, both ligand atoms and projected positions of 
complementary site atoms are considered as hydrogen bonding features. The handling of 
conformational flexibility is also similar to that used in DISCO, with each molecule being 
represented by a set of low energy conformations that are subsequently treated as being rigid. 
Conformations can be generated using the Poling technique [8] that ensures broad coverage 
of conformational space, or by using any external structure generation program. 
Each molecule is treated as reference molecule in turn. Different configurations of feature 
points are identified in the reference molecule using a pruned exhaustive search which starts 
with small sets of features and extends them until no larger configuration is found. Each 
configuration is then compared with the remaining molecules in an attempt to identify 
configurations that are common to all molecules. A molecule matches a configuration if it 
possesses a set of features that can be superimposed on the configuration. The requirement 
that all molecules match all features in the configuration can be relaxed so that not all 
molecules are required to possess all the features identified in the pharmacophore. Thus, the 
assumption is that a molecule can be active despite lacking a feature relevant in the binding 
of other molecules. The resulting hypotheses are ranked using a combination of how well the 
molecules map onto the proposed model and the rarity of the model.  
GASP [9,10] is based on a genetic algorithm and differs from both DISCO and Catalyst in its 
handling of conformational flexibility which is performed on-the-fly. Thus each molecule is 
input as a single conformation and random rotations and a random translation are applied to 
the molecules before any superimposition is made. The pharmacophoric features in the 
molecules are determined (hydrogen bond donor protons, acceptor lone-pairs, and ring 
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centres including projected site points). The molecule with the least number of 
pharmacophoric features is chosen as the base molecule to which the other molecules are 
fitted (cf the reference molecule in DISCO).  
A chromosome in GASP encodes the angles of rotations of the rotatable bonds in all of the 
molecules and the mapping of the pharmacophoric features in the base molecule to 
corresponding features in each of the other molecules. For a data set of N compounds the 
chromosome consists of 2N-1 strings: N binary strings to represent the conformations of the 
molecules and N-1 integer strings that represent the mapping from the base molecule to each 
of the other molecules. The length of the integer strings is determined by the number of 
pharmacophoric features in the base molecule. The fitness function first generates 
conformations for each molecule and then uses a least-squares procedure to overlay each 
molecule onto the base molecule using the mappings. Fitness is then a combination of the 
number and similarity of the overlaid features, the volume integral of the overlay and the van 
der Waals energy of the molecular conformations. Genetic operators are used in an attempt to 
evolve solutions that maximise the fitness function and thus correspond to the best possible 
structural overlay. 
Each run of the GA in GASP generates a single solution pharmacophore and each feature in 
the pharmacophore must be present in each of the molecules. Since a GA is a non-
deterministic method which is not guaranteed to find the global minimum solution, it is 
possible that a different solution is found each time the GA is run. Typically, therefore, 
GASP will be run several times with the same data and to generate a family of solutions 
which can be ranked based on their fitness scores. 
Method 
As described in the Introduction, pharmacophore generation programs are typically used 
when a series of actives compound is known but the 3D structure of the receptor site is 
unknown. In this situation, the true pharmacophore is unknown and hence it can be difficult 
to judge the quality of the hypotheses suggested by a program. In this study, the programs are 
therefore compared on their ability to generate known pharmacophores which have been 
deduced from protein-ligand complexes extracted from the Protein Data Dank [11]. Five 
different protein families were used in the evaluation. For each family, the pharmacophore 
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responsible for activity was deduced by aligning the complexes using the active sites of the 
proteins and by referring to the literature. The procedure adopted is described below. 
A protein-ligand complex was chosen as a starting point and the similar binding site function 
of Relibase+ [12] was used to find other protein-ligand complexes in the same family. A 
protein-ligand complex was discarded if the ligand: had molecular weight > 600; was too 
flexible (> 16 rotatable bonds); was covalently bound to the receptor; or was peptidic. The 
ligands were then extracted from the complexes and where there were more than ten ligands a 
diverse subset was selected using the hierarchical cluster analysis available in Sybyl [13]. 
Ligands, in their bound conformation, were clustered based on their CoMFA steric fields 
only. The clusters were then analysed by eye and a small set of molecules chosen from which 
to derive the known pharmacophore. The protein families and the numbers of ligands in each 
data set are given in Table 1. 
Once a set of ligands had been identified for a protein family, the pharmacophoric features 
for each ligand were deduced by examining the protein-ligand complex in Relibase+ and by 
reference to the literature. A a target pharmacophore was then defined as the set of 
pharmacophoric features that is common to all ligands. Each of the three programs was then 
tested on its ability to generate the target pharmacophore. 
Each program was evaluated in two phases. The first phase consisted of using the bound 
conformations and performing a Rigid Search (see later for details on GASP). The rationale 
for carrying out the Rigid Search is that if the target pharmacophore cannot be created using 
the bound conformations, it is unlikely that it will be found when the conformations of the 
ligands are relaxed. The second phase was to carry out a Flex Search in which the 
conformational space available to the ligands is explored. The details of each of these phases 
varies slightly from one program to another due to the implementation details and the 
variation allowed in the searches. The specific details for each program are given below. 
Catalyst/HipHop is referred to as Catalyst from hereon. Catalyst [14] allows the manual 
definition of a pharmacophore using a single compound. This was done using the bound 
conformation of the ligand with the most pharmacophoric features. The manually determined 
pharmacophore should consist of at least a subset of the features included in the target 
pharmacophore and can be used to aid the visual inspection of the pharmacophores generated 
subsequently. Features in the target pharmacophore can be missing from the manually 
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determined pharmacophore due to limitations of the program (see later). Generating the 
manual pharmacophore can thus give an insight into what is achievable during the automated 
steps. In the Flex Searches, conformational models were created using the Poling method 
available within Catalyst. Catalyst typically produces a number of possible pharmacophore 
hypotheses which can be clustered. The clusters were examined to identify the best 
hypothesis, that is, the hypothesis that is most similar to the target pharmacophore.  
In DISCO [15] conformers were generated for the Flex Searches using the Multisearch and 
REJECT features. The REJECT feature removes duplicates to leave a set of unique low 
energy conformers [4]. DISCO also produces a number of possible pharmacophores. The 
hypotheses were grouped on the basis of the assignment of atoms to features and a text search 
on the model characteristics was used to identify the group(s) of hypotheses with the best 
assignment of features. The hypotheses in the identified groups were then examined in more 
detail to find the hypothesis that most closely matches the target hypothesis. 
The procedure adopted for the GASP [9,10,16] runs was as follows. Firstly, since 
conformational analysis is performed on the fly it was not possible to conduct a fully rigid 
search. It is possible, however, to hold a single compound as rigid and thus the Rigid Search 
was simulated by fixing the most flexible compound in its bound conformation. CONCORD 
[17] was used to generate a single low energy conformation for each ligand prior to the Flex 
Searches.  
The definition of a pharmacophore hypothesis in GASP is stricter than in DISCO or Catalyst 
since all ligands are required to match all features in the pharmacophore. This can make 
finding the target pharmacophore more difficult especially for large numbers of ligands. (In 
DISCO, although all molecules included in the hypothesis have to match all the features, it is 
possible to exclude some molecules from the hypothesis). Thus, it is recommended for GASP 
that the datasets are limited to between two and four ligands [18] and hence if the target 
pharmacophore was not found using all ligands the dataset was divided into subsets based on 
common features and each subset was used in a separate search.  
GASP generates a single solution per run. However, since it is based on a non-deterministic 
algorithm it is possible that a different solution can be found for each run. Thus five runs 
were carried out for each dataset for the Rigid Searches and 15 runs for the Flex Searches. In 
each case all solutions were examined to identify the best solution. 
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Evaluation 
The main criteria on which the programs are judged is their ability to generate the target 
pharmacophores. However, even when the target pharmacophore is known, evaluating the 
"goodness" of a hypothesis is still a complex task. Here, various criteria are applied to 
evaluate the best hypotheses that are generated. All features in a hypothesis that correspond 
with features seen in the ligands are recorded and a Hit is flagged if all the features of the 
target pharmacophore have been identified. Two criteria are used to judge the quality of a hit. 
Firstly, the RMSD between the best hypothesis and the target pharmacophore is recorded (as 
Fit in the results tables). Secondly, the extent to which the hypothesis is representative of the 
ligands is given by the number of misses in the hypothesis with a Miss being recorded each 
time a feature is missed by a molecule (either the feature is missing entirely or the wrong 
functional group is assigned to the feature). All the programs assign a score to the hypotheses 
generated which can be used to rank the output, although the actual scoring functions used 
vary from one program to another. The position of the best hypothesis in the ranked output is 
also recorded (as Rank in the results tables). Catalyst provides an additional way of validating 
a hypothesis based on the mappings score for a ligand. For a given hypothesis there can be 
several alternative mappings between a ligand and the features of the hypothesis and these are 
presented in rank order as the mapping number. This number is not recorded in the results 
tables but is sometimes referred to in the discussion. Finally, the hypotheses were judged in a 
more qualitative manner, as detailed in the discussion. 
Results 
Thrombin 
Searches using Relibase+ identified 65 examples of human-alpha thrombin complexed with 
small ligands. The dataset was reduced to 37 complexes by removing 28 complexes that had 
covalent interactions between the ligand and the protease. The 37 ligands were extracted and 
clustered into 7 clusters. Two of the clusters were removed: one containing ligands that 
interact with the protease via hydrophobic interactions only; the other containing relatively 
large and very flexible ligands. A total of 7 ligands were chosen from the remaining clusters 
to create a data set which contains diverse, small, non-peptidic ligands. The ligands together 
with the PDB codes for the protein-ligands complexes are given in Table 2. 
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The key interactions involved in binding are shown in Table 3 with reference to ligand 1cv4 
and the corresponding features present in each of the ligands are highlighted in Table 2 [19-
27]. The target pharmacophore was defined as the four feature pharmacophore consisting of 
the features B, H1, H2 and H3 which are the features that are common to all ligands. The 
results are shown in Table 4 and discussed below. 
Catalyst. 
Rigid Search. When Catalyst was configured to search for four feature hypotheses two best 
hypotheses were generated. Both hypotheses include the basic region B, the donor D1 and the 
acceptor A1. They differ in the hydrophobic regions identified, with the first having a 
hydrophobic region corresponding to H2 and the second identifying the hydrophobic region 
corresponding to H3. Neither hypothesis includes the feature H1 since it is too close to the 
basic region to be identified, although in both cases the region can be deduced from the 
alignment, hence it is recorded as found in Table 4. Thus the target pharmacophore is found. 
Flex Search. Low energy conformers were generated for the ligands with the maximum 
number per molecule limited to 255. The number of conformers per ligand is shown in Table 
5. Catalyst was then configured to generate 120 hypotheses. All the resulting hypotheses 
include five or six features with either two or three hydrophobic regions, one or two donors, 
and one or two acceptors. None of the hypotheses contain a positive ionisable group, 
although this feature is identified as a donor. The absence of the positive ionisable group is 
surprising since the feature was identified during the Rigid Search and it is possible that the 
hypotheses found previously were missed due to insufficient sampling of conformational 
space or that they would be found at ranks lower than 120 if the number of hypotheses to the 
generated had been increased. 
The hypotheses which contain two acceptors all have an acceptor next to donor D1 that is not 
present in the target pharmacophore. In most cases, it is the carbonyl oxygen next to the N-H 
corresponding to D1 that maps to this feature, except for 1d4p (which only has one acceptor); 
1dwd (where it is the carbonyl next to the piperidine group); and 1fpc (where it is the 
carbonyl oxygen shown as A1). This feature is not involved in the binding but is more likely 
present for steric reasons. 
The best hypothesis produced, i.e., the one closest to the target pharmacophore, is ranked 
second (the top ranked hypothesis contained two acceptors). This hypothesis consists of two 
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hydrophobic regions (H2 and H3); two donors (one corresponding to D1 and one 
corresponding to the positive ionisable group B); and one acceptor (A1). The hypothesis 
closely resembles those generated in the Rigid Search, except that both hydrophobic regions 
H2 and H3 have been determined. Again, although H1 was not identified it can be deduced 
from the overlay.  
Figure 1 shows a schematic of the Catalyst generated hypothesis, together with the 
corresponding five feature pharmacophore created manually from the bound conformation of 
1c4v. The main difference between the two hypotheses (apart from the positive ionisable 
group being replaced by a donor) is that the former positive ionisable group is now further 
away from the other features of the hypothesis. Apart from this, the molecules all map well to 
the hypothesis, with the correct features being assigned to each molecule, except for: 1d9i 
which has an incorrectly assigned N-H donor, although the N-H in question does hydrogen 
bond with a solvent molecule; and 1fpc where the SO2 group maps to A1 instead of the 
correct C=O acceptor. Thus, the number of misses is given as two. 
GASP 
Rigid Search. The two ligands 1c4v and 1tom were used with 1tom held rigid. The 
pharmacophore produced consists of 8 features due to the large number of functional groups 
in common between the two ligands. The features include five acceptors (including A1); two 
donors (one corresponding to D1 and one corresponding to the positive ionisable group B); 
and one correctly assigned hydrophobic region (H3). GASP fails to recognise the other 
hydrophobic regions due to its limited definition of hydrophobicity which is restricted to 
aromatic centres. However, both H1 and H2 can be readily deduced by the user from the 
alignment and as for Catalyst they are given as matches in Table 4. Thus the target 
pharmacophore is given as found. 
Flex Search. All seven ligands were used initially, however, poor results were obtained, 
presumably due to an overload of data coupled with a choice of parameter settings that did 
not allow a full search of conformational space. Thus the data set was divided into the three 
subsets as shown in Table 6 and 15 runs were carried out for each set. The ligands in Set 1 
contain all six pharmacophoric features. Set 2 consists of the remaining three ligands and Set 
3 was used to see if GASP could deduce all the interactions present in 1d9i and 1dwd.  
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The best hypothesis produced for Set 1 is at rank one and consists of two pharmacophoric 
features only, H3 and an acceptor that is not present in the binding site. H1 and H2 are not 
deduced by GASP due to the limited definition of hydrophobicity (as for the Rigid Search), 
however both of these regions can be deduced by the user from the overlay, as can the other 
features B, D1 and A1. Only one of the 15 solutions (rank 14) identifies feature B (as an 
acceptor). Three of the solutions (rank 4, 11 and 15) identify D1 and another three identify 
A1 (rank 5, 6 and 13). 
The best hypothesis for Set 2 is at rank two and includes feature B (identified as an acceptor) 
and feature H3. Again features H1, and H2 are not identified by GASP but they can be 
deduced by the user from the overlay. Again an acceptor is identified that is not present in the 
binding site. The top ranked solution does not identify feature B. 
The best overlay for Set 3 (rank 3) identified B (as a donor); D1; A1 and H3. Features H1 and 
H2 can be deduced from the overlay. Extra features not present in the binding site are also 
identified including 4 acceptors that correspond to two carbonyl groups. The top two 
solutions both miss the features B and A1. 
Combining the results of the three sets: H3 is identified in all three sets and H1 and H2 can be 
deduced by the user in all the sets; and Sets 2 and 3 identify the feature B (as an acceptor and 
donor respectively).  
DISCO 
Rigid Search. The target pharmacophore containing all features for all molecules could not be 
found. Models were obtained when DISCO was allowed to exclude two molecules (1d9i and 
1tom were excluded) with 1c4v used as the reference molecule, and the best of these is 
reported in Table 4 as Set 1. Three ligands, 1tom, 1c4v, and 1d6w, were then used to form 
another pharmacophore model, with 1c4v again used as reference, also shown in Table 4 as 
Set 2. 
The features in both models are representative of the binding site in thrombin, but the 
alignments are more realistic in the second model. This is probably a direct result of there 
being fewer molecules to align. Neither model contains the positive ionisable group (the 
version of DISCO used does not recognise ionisable features), although the feature is 
recognised as both a donor and an acceptor. The hydrophobe H2 is present in both models. 
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The second model shows the correct acceptor A1 but lacks the hydrophobe H3 which is 
found in the first model. When 1d4p was used as the reference molecule (Set 3), and 1d9i and 
1tom were excluded, all the features except D1 and H3 were found. 
Flex Search. The number of conformers generated for each ligand is given in Table 5. Ligand 
1d4p was used as the reference molecule (the default choice since this is the least flexible 
molecule). This resulted in a total of 452 models divided into 29 groups. All the models 
consist of a donor and acceptor in place of the positive ionisable group, but the rest of the 
features vary from model to model and include features present in the target pharmacophore 
as well as the non-existent C=O acceptor found by both GASP and Catalyst. Varying the 
reference ligand had little effect on the models generated, and although, it is possible to 
determine the target pharmacophore through viewing many of the models generated, no one 
model is sufficient. A representative model consisting of features B, H2 and A1 is reported in 
Table 4. 
Summary. The hypothesis generated by Catalyst is the closest to the target pharmacophore. 
GASP performed reasonably well, although the ligands had to be divided into subsets and a 
certain amount of detective work was required on the different hypotheses derived in order to 
obtain a reasonable model. DISCO was similar to GASP in that a combination of models was 
required in order to deduce a reasonable model, however, the models derived where of a 
poorer quality that the GASP models. Thus the order of performance of the programs on the 
thrombin ligands is given as Catalyst>GASP>DISCO. The best hypothesis generated by each 
of the programs is illustrated in Figure 2. 
CYCLIN DEPENDENT KINASE 2 (CDK2) 
Nine human cyclin dependent kinase 2 complexes were found using Relibase+. Three of 
these were removed since they contain ligands with heavy atoms other than phosphor or 
sulphur, leaving a total of 6 ligands for the data set, one of which (1fin) is the naturally 
binding ligand. The data set can be seen in Table 7. 
The key interactions involved in binding are shown in Table 8 with reference to ligand 1aq1 
and Table 7 shows the corresponding features present in each ligand [28-32]. The target 
pharmacophore was defined as the two feature pharmacophore consisting of the features A1 
and H1. The results are shown in Table 9 and discussed below. 
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Catalyst. 
Rigid Search. The pharmacophore generated using the bound conformations of the ligands 
includes the features D1, A1 and H1 hence the target pharmacophore is found. All features lie 
in the same plane as in the target pharmacophore although the hydrophobe is located further 
away from the hydrogen bonding features (indicated by the RMS Fit). The naturally 
occurring ligand (1fin) does not match the pharmacophore correctly. This can be due to its 
large size relative to the other ligands and the presence of the tri-phosphate region which is 
rich in hydrogen bonding features which Catalyst prefers to map to the hydrogen bonding 
region of the pharmacophore. 
Flex Search. The number of conformations produced for each ligand is shown in Table 10. 
When all ligands were included 67 hypotheses were found and when 1fin was excluded 120 
hypotheses were found (the previous 67 plus new lower ranking models). In both case, the 
best hypothesis is ranked second. The features D1, A1 and H1 are found together with two 
additional acceptors that are close to A1 and D1. In fact all ligands except 1aq1 have atoms in 
this region that are capable of acting as acceptors. All the hydrogen bonding features lie in 
the same plane but the hydrophobe now sits above the plane by approximately 1.8 Å. 
Two of the ligands, 1fvv and 1di8, involve high ranking mappings, 12 and 24 respectively. 
The earlier mappings for these ligands had the wrong assignment of atoms to features: the 
higher ranking mappings for 1fvv have the tricyclic region shifted relative to the bound 
conformation with the tail of the molecule mapping to the hydrogen bonding features; for 
1di8 the higher ranking mappings involve incorrect assignment of atoms to A1. 
GASP 
Rigid Search. GASP was run with ligands 1e1v, 1e1x and 1aq1, with the most 
conformationally flexible, 1e1x, held rigid. The best hypothesis was the top ranked 
hypothesis and consisted of features H1, A1, and D1. Thus the target pharmacophore is 
found. 
Flex Search. The data set was divided into the four subsets as shown in Table 11. The best 
hypothesis found for Set 1 is at rank nine. The features identified are D1, A1, D2 and H1 
along with an additional acceptor. The best hypothesis for Set 2 is the top ranking solution 
and the features identified correctly are D1, A1 and H1. The hypothesis includes five 
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additional features (four donors and one acceptor) which correspond to the feature rich region 
of 1fin and the ether region of 1aq1. The best hypothesis for Set 3 is ranked 13 and is the first 
hypothesis found for this set that has the ligands oriented correctly with respect to each other. 
The features identified are A1 and H1 along with an additional acceptor. All of the 
hypotheses produced for Set 4 are poor. In all cases ligand 1di8 is aligned with the portion of 
1fvv that sits in the hydrophobic cavity and is not involved in hydrogen bonding. Thus, 
although the hydrophobe H1 and donor D3 have been identified for 1di8 they do not 
correspond to the correct features in 1fvv. 
DISCO 
Rigid Search. Ligand 1elx was used as the reference molecules and the best hypothesis 
consists of donor D1, acceptor A1 and hydrophobe H1 and hence the target pharmacophore is 
found. However only three of the six ligands map correctly to the hypothesis. The number of 
misses is given as eight since the hydrophobic region of 1di8 is deduced but the alignment of 
the ligand is wrong. 
Flex Search. The number of conformations produced for each ligand is shown in Table 10. A 
total of 1692 models were generated that were arranged in 29 groups 7 of which contain 
features that represent the target pharmacophore. The first model to contain features A1 and 
H is ranked 52. However the best model (i.e., the one that had the highest number of ligands 
correctly mapped to the model) is at rank 1502. The model consists of hydrophobe (H1), an 
acceptor atom/donor site pair (A1), and an acceptor site that corresponds to D1, although it 
points in the wrong direction. The model has the following incorrect assignments: in 1aq1 
only H1 is correctly identified and it is the ether region of the molecule that is assigned to the 
H-bonds; in 1di8 only H1 is correct and the wrong atoms have been assigned to the H-
bonding features of the model; 1fvv is mapped incorrectly. Thus the total number of misses is 
given as seven. In 1e1v, 1e1x and 1fvv the acceptor site feature of the model corresponding 
to D1 is pointing in the wrong direction although these are not recorded as misses. 
Summary. Catalyst was successful in generating good models of the pharmacophore, 
although the best model contains two extra HB-acceptors. DISCO was also successful at 
generating the target pharmacophore and also deduced donor D2 which is missing from the 
Catalyst model, however, the rank position of the best model is very low (1502) and only 
three of the ligands map to the model correctly. The models produced by GASP are very 
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good for Sets 1, 2, and 3, with all the features of the target pharmacophore identified in each 
set. The model for Set 4 is rather disappointing, and is most likely due to the differences in 
sizes of the ligands used. Overall, all three programs performed well for this data set. The 
order of performance of the programs is given as: GASP > Catalyst > DISCO. DISCO is 
placed last because it only maps three of the ligands correctly, and because of the low ranking 
of the model and GASP is placed higher than Catalyst because it has fewer misses overall 
than Catalyst. The best hypothesis generated by each of the programs is illustrated in Figure 
3. 
DIHYDROFOLATE REDUCTASE (DHFR) 
A search of Relibase+ for human DHFR resulted in 11 hits which consist of 6 unique ligands. 
The resulting data set can be seen in Table 12. 
The key interactions involved in binding are summarised in Table 13 with reference to ligand 
1ohk and Table 12 shows the corresponding features present in each ligand [33-37]. The 
target pharmacophore consists of D1, A1, H1, and H2. The results are shown in Table 14 and 
discussed below. 
Catalyst 
Rigid Search. The best hypothesis consists of the features D1, A1, D2, H2 and A2. The 
hydrophobe H1 which is present in the target pharmacophore was not found. This is due to 
the fact that it is too close to the hydrogen bond features for Catalyst to recognise it. It can, 
however, be easily deduced from the alignment hence the target pharmacophore is given as 
found in Table 14. However, not all of the molecules match all of the features correctly. The 
donor D1 is not recognised in 1ohk and 1boz; in 1drf and 2dkf the carbonyl group of the 
pteridine ring is incorrectly assigned as A1; and in 1dhf the wrong N is assigned to D2. 
Flex Search. The number of conformations produced for each ligand is shown in Table 15. 
All 120 hypotheses generated consist of at least one hydrophobe, two donors and three 
acceptors. Only one of the hypotheses includes acceptors in the region of A2 and A3, and 
even then the ligands are poorly mapped to the hypothesis. The best models are found at 
ranks two and nine. 
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Hypothesis two consists of the features D1, A1, D2, H2 and A2. Ligands 1drf and 2dhf have 
incorrect assignments to A1 since in both cases it is the C=O group and the N atom on the 
opposite side of the ring are shown as acceptors; and in 2dhf the NH of the tetra-hydro-
pyridyne ring is incorrectly assigned to D2. Thus the number of misses is given as three. 
Additional features not in the target pharmacophore are found in ligands 1hfp (the ring O and 
the N between the two NH2 groups are shown as acceptors); in 1boz and 1dlr the pteridine 
ring has an extra donor and acceptor; and 1ohk shows the pteridine ring with two extra 
acceptors. 
Hypothesis nine consists of the features D1, A1, D2, H1, A2 and A3. The best mappings of 
ligands 1hfp, 1drf, 2dhf and 1ohk are at ranks 78, 40, 97 and 42 respectively. In all cases, the 
earlier mappings have incorrect assignments of atoms to A2 and A3. In ligands 1boz and 1dlr 
the ether oxygens are incorrectly assigned as acceptor A2 thus the number of misses is 
recorded as two. 
GASP 
Rigid Search. Ligands 1hfp and 1ohk were used. The best solution is the top ranking solution 
and all of the features present in the binding site have been identified: D1, A1, D2, D3, H1, 
H2, A2, A3 and D4. A number of additional features have also been identified due to the high 
degree of similarity of the two ligands. 
Flex Search. The data set was divided into the three subsets as shown in Table 16. The best 
hypothesis found for Set 1 is ranked top. The features identified are D1, A1, H2, A2, A3 and 
D4. The remaining hydrophobe (H1) can be deduced from the overlay. D2 and D3 are 
missing from the hypothesis since neither of the two ligands have this interaction. Several 
other pharmacophore points (four donors and nine acceptors) have also been identified due to 
the high degree of similarity between the two ligands. The best solution for Set 2 is ranked 
second with all nine features correctly identified, along with some additional features. The 
first ranked solution is very similar except that the direction of acceptor A2 is incorrect - it is 
shown pointing towards the pteridine ring instead of away from the ring. The best solution for 
Set 3 is the top ranking solution and all of the correct features are identified (except for A2; 
A3 and D4 which are not present in the ligands). 
 15
Combining the results from the three sets the pharmacophore can be deduced as all the 
features listed in Table 14 together with an additional donor and acceptor in the pteridine ring 
region and a donor and donor/acceptor pair in the 'tail end' of the ligands. 
DISCO 
Rigid Search. The best models were found when 1boz was used as the reference model and 
DISCO was forced to find the hydrophobic regions H1 and H2. The first model consists of 
three hydrophobic centres, H1 and H2 and a third hydrophobic close to H1. In fact only one 
hydrophobe should be found in this region since in their bound conformations the ligands1drf 
and 2dhf are aligned such that only one of their two rings overlap with the corresponding ring 
systems of the other ligands. The acceptor A1 is also identified. The second model consists if 
the same three hydrophobes, an acceptor atom that is not present in the known 
pharmacophore and a donor site that corresponds to acceptor A2. 
Flex Search. The reference ligand was 1ohk and 51 models were produced, arranged in 19 
groups which could be further clustered into two sets, one that contains two hydrophobes, and 
one that contains one hydrophobe. In both cases, the hydrophobes correspond to the feature 
rich rings, with the more accurate models being those that contain only one hydrophobe 
which represents H1. When a second hydrophobe is found it is incorrect and is due to the 
incorrect alignment of ligands1drf and 2dhf as in the Rigid Search. 
The two best models produced are at rank one and rank 15 respectively. The features that 
have been deduced correctly are: D1 (shown by a donor atom and an acceptor site), A1 
(shown by an acceptor atom and a donor site) and H1. Additional features have been deduced 
in this region of the ligands, due to the feature rich nature of the rings, including two acceptor 
atoms, a donor site, and an acceptor site. The final feature deduced is an acceptor atom in the 
tail region of the ligands, that corresponds to the feature A3 which is correctly assigned in 
in just two of the ligands, 1hfp and 2dhf, neither 1boz nor 1dlr have this feature, and it has 
been incorrectly assigned in the case of 1ohk and 1dfr, hence the number of misses is given 
as two. D2 and D3 can be deduced from the overlays since the NH2 groups that correspond to 
these features are very close together. The reason they have not been identified is because 
these features are not common to all ligands, they are not present in 1drf and 2dhf. 
The features identified in the model at rank 15 are very similar to those in the top ranking 
model. The only difference is that there is a donor site instead of an acceptor atom in the tail 
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region of the ligands although this feature has only been assigned correctly in one of the 
ligands, 1hfp, where it represents A2. The other features identified correctly are D1, A1, and 
H1. Again, D2 and D3 can be deduced. The remaining features, H2, A2, A3 and D4, are not 
identified because of the way the ligands have been overlaid and because A3 and D4 are not 
present in two of the ligands, 1boz and 1dlr. 
Summary. GASP performed the best for this data set, since it is the only program that 
identified all the features of the pharmacophore. Catalyst is ranked second since two features 
were missed: D3 as a results of the NH2 groups being restricted to forming only one hydrogen 
bonding interaction; and D4 which is missed because Catalyst does not recognize carboxylic 
OH groups as being hydrogen bond donors. DISCO was the worst of the three programs, and 
was only able to identify the features D1, A1, H1 and A3. The best hypothesis generated by 
each of the programs is illustrated in Figure 4. 
HIV-1 Reverse Transcriptase 
Searches in Relibase+ resulted in 47 protein-ligand complexes being identified. The 47 
ligands were extracted and clustered and a data set of 10 ligands that bound in the non-
nucleoside binding site was obtained as shown in Table 17. 
The key interactions involved in binding are summarised in Table 18 with reference to ligand 
1klm and Table 17 shows the features present in each ligand [38-47]. The only feature which 
is common to all ligands is the hydrophobe H and this thus represents the target 
pharmacophore. The results are shown in Table 19 and discussed below. 
Catalyst. 
Rigid Search. The best hypothesis produced using the bound conformations consists of a 
donor and acceptor corresponding to features D1 and A1 and three hydrophobic regions, two 
of which represent H1 and the third which is incorrect. 
Flex Search. The number of conformations produced for each ligand is shown in Table 20. 
Two best hypotheses were found at ranks one and eighteen. Both contain a donor, an acceptor 
and three hydrophobes. The top ranking hypothesis has the acceptor and donor correctly 
identified, however, the hydrophobes are located incorrectly and do not correspond to H1. In 
addition, the top ranked hypothesis has the following incorrect assignments of ligands to 
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features: 1vru is shown as forming two hydrogen bonds when it interacts via hydrophobic 
interactions only; 1rt3 is shown as having one hydrogen bonding feature which is incorrect; 
the first mapping of 1klm to the hypothesis that shows the correct assignment to the donor 
and acceptor features is at mapping 32 with all higher mappings involving the SO2 group; the 
first mapping of 1tvr that shows only the NH group as a donor is mapping eight. 
The hypothesis at rank 18 has the donor and acceptor and also has a hydrophobe in the right 
location to represent H1. However, it has the following incorrect assignments of ligands to 
features: mapping 48 of 1ddt is the first mapping with the hydrogen bonds pointing in the 
same direction; 1rt3 is shown as having an acceptor interaction when this is not the case. 
Barnum et al (1995) have reported on the application of Catalyst/HipHop to generate 
hypotheses for HIV-1 reverse transcriptase. Their best hypothesis was a five feature 
hypothesis consisting of an acceptor and 4 hydrophobes, in constrast to the five feature 
hypothesis found here which consists of a donor, an acceptor and three hydrophobes. 
GASP 
Rigid Search. Two subsets of ligands were used in the Rigid Search as shown in Table 21a. 
All the overlays produced for Set 1 are very similar. The features identifed are D1/2 and H. 
Two of the ligands, 1dtt and 1rt5 have the features assigned to the correct atoms, but in the 
third ligand, 1klm, the feature D1/2 has been assigned to the wrong N atom, it has been 
assigned to the N next to the SO2 group when it should be the N in the indole ring.  
The overlays produced for Set 2 are also very similar to each other. The features identified 
are a hydrophobe (which represents H) and two acceptors. In 1fk9, the carbonyl O 
corresponding to A is identified as having two acceptor interactions. In 1klm and 1bqm, the 
acceptors do not correspond to the atoms that are responsible for this feature. In the case of 
1bqm, this is due to the acceptor being a S atom which is not recognised as an acceptor by 
GASP. 
Flex Search. The data set was divided into the five subsets shown in Table 21b. The overlays 
produced for Set 3 are all very similar. The top ranked solution consists of two acceptors, in 
1fk9 and 1klm these correspond to the carbonyl groups and thus acceptor A has been deduced 
correctly. In 1bqm, however, the acceptor is incorrectly assigned to the carbonyl group when 
it is actually the C=S group that interacts with the receptor. This again demonstrates the 
 18
limitation of GASP whereby the program does not recognise sulfur atoms as being able to 
form hydrogen bonds. In addition, although H was not identified it can be deduced from the 
overlay. 
The best solution for Set 4 is also the top ranking solution. The features consist of D, H and 
an incorrectly assigned acceptor. In both ligands, a N atom is assigned as an acceptor whereas 
A should correspond to the C=S groups. 
Set 5 consists of two ligands that interact via hydrophobic interactions only (1rt3 and 1vru). 
The best solution (ranked first) correctly identifies the hydrophobic interaction H. In addition, 
three acceptors are identified that are not present in the binding site. The additional features 
are due to the alignment of functional groups in the ligands and will increase the fitness score 
of the overlay. 
The best solution for Set 6 is at rank five and consists of two hydrophobes, which represent 
H, two acceptors, one of which corresponds to A and a donor, which corresponds to D. The 
additional acceptor is due to the way the ligands are aligned. 
The solutions for Set 7 are very similar to one another. The top ranked solution consists of a 
donor, which corresponds to D, and an acceptor at the opposite end of the ligands. The 
hydrophobic region, H, has not been deduced, since in one ligand it is due to a non-aromatic 
interaction which is not recognised by GASP, however, it is possible for the user to identify 
this region from the overlay. In addition, the user may deduce the existence of an acceptor 
next to the donor D. This feature is present in 6 of the other ligands as A, but is not part of the 
binding mode for the two ligands in this set. 
DISCO 
Rigid Search. Two models were found when 1fk9 was used as the reference ligand. The best 
model (rank two) consists of three features, a donor atom and acceptor site which correspond 
to the interaction D, and a donor site which corresponds to the acceptor to LYS101/103. The 
acceptor atom itself (A) has not been found, due to the way in which the ligands have been 
overlaid: the donor site feature of the ligands are all located in close proximity to one another, 
however the corresponding acceptor atoms are spread out and are presumably outside the 
(default) tolerance range. The most likely reason that the hydrophobe is missed is due to the 
incorrect alignment of 1ep4 which has its aromatic rings positioned wrongly. However, the 
 19
hydrophobe H can be deduced by the user since for all of ligands, except for 1ep4, the rings 
are located in the same position, behind the hydrogen bonding features. 
Flex Search. The number of conformations produced for each ligand is shown in Table 20. 
1fk9 was assigned as the reference structure (the default choice), and 71 models were 
produced which were arranged in 21 groups. Five of these groups consist of features that are 
present in the binding site.  
The highest ranking model in the first group is at rank 29. The model consists of features H 
and A1 or A2 however only two of the ligands, 1fk9 and 1ep4, have correct assignments of 
atoms to features. Two ligands are excluded from the model, 1vru and 1tvr. For the remaining 
ligands, the incorrect assignments are as follows: in 1bqm the ether O is shown as the 
acceptor; in 1dtt the N in the ring next to the ether O is shown as the acceptor; in 1klm the N 
next to the SO2 group is shown as the acceptor; in 1rt1 the ether O is shown as the acceptor (a 
result of the hydrophobe being assigned to the aromatic ring next to the ring which contains 
the H-bonding features of 1fk9); two acceptors are found in 1rt3 although this ligand interacts 
via hydrophobic interactions only; in 1rt5 the O next to the butyl group is shown as the 
acceptor. The number of misses is recorded as six. 
The highest ranking model in the second group is at rank 47. The model consists of features 
H and D with the acceptor A being deducible from the overlay. One ligand is mapped 
incorrectly (1vru which is shown as interacting via a donor when it interacts via the 
hydrophobic interaction only). Ligands 1rt1 and 1rt3 were excluded from the mapping. 
The highest ranking model in the third group is at rank 58. The model consists of features H 
and A. Two ligands are excluded from the model (1rt3 and 1rt5) and four ligands have 
incorrect assignments: 1bqm where the ether O is shown as the acceptor; 1dtt where the ether 
O is shown as the acceptor; 1klm where the N next to the SO2 group is shown as the acceptor; 
and 1vru which is shown as having an acceptor when it interacts via the hydrophobic 
interaction only.  
The highest ranking model in the fourth group is at rank 66. The model consists of features D 
and A. Four of the ligands are mapped to the model correctly, 1fk9, 1tvr, 1ep4 and 1rt1 
Ligands 1bqm and 1rt3 are excluded. 
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The highest ranking model in the fifth group is at rank 68. The model consists of features H 
and D. Ligands 1vru and 1rt5 are excluded and correct assignments are found for ligands 
1fk9, 1bqm, 1tvr, and 1rt1 only. 
Summary. The order of performance is given as Catalyst > GASP > DISCO.   Catalyst is 
ranked first since the target pharmacophore is found; the highest number of ligands are 
correctly mapped; and the least amount of user input was required. GASP is ranked above 
DISCO because, although the results of the different runs have to be combined, the models 
produced are generally of a better quality due to the fact that GASP takes into account steric 
overlap during the pharmacophore generation procedure. The best hypothesis generated by 
each of the programs is illustrated in Figure 5. 
Thermolysin 
Searches in Relibase+ resulted in 40 protein-ligand complexes being identified. Several of the 
ligands consisted of either metal ions or 2-4 atoms and these complexes were discarded 
leaving a total of 22 ligands. After duplicates were removed and clustering a set of six ligands 
was obtained as shown in Table 22. 
The key interactions involved in binding are summarised in Table 23 with reference to ligand 
4tmn and Table 22 shows the features present in each ligand [48-52]. The target 
pharmacophore consists of features M, A1, H and A2 where feature M represents binding to 
the Zn+ ion of the receptor and involves two acceptors in the ligands. The results are shown 
in Table 24 and discussed below. 
Catalyst 
Rigid search. The best pharmacophore is at rank 26, this is the first hypothesis in the list to 
have an acceptor feature in a position and direction to represent the feature A1. Other features 
present in the hypothesis are two acceptors that represent M, and a hydrophobe that 
corresponds to H. 
Flex Search. The number of conformations produced for each ligand is shown in Table 25. A 
total of 120 hypothesis were generated all consisting of four acceptor features and one 
hydrophobe. The best solution is ranked eighth and is the first hypothesis to contain features 
in the correct position to represent the features of the target pharmacophore, H, A1 and M. 
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An extra feature was also found that corresponds to A3 in four of the ligands that have this 
feature (7tln and 1hyt are both missing this feature). The feature A2 has not been identified 
since this corresponds to one of the O atoms that is also responsible for feature M, and 
Catalyst only assigns one acceptor feature to an O atom. The first mapping of 5tln that has the 
correct atom assignments of features M and A1 is at mapping 33; in 5tmn and 4tmn only one 
of the two acceptors representing M have been assigned correctly, in both cases the ether O is 
incorrectly assigned as an acceptor. 
In some of the models, A2 is identified, together with one acceptor representing M, however, 
the other acceptor features present in the hypotheses are not in locations where they could 
correspond to the remaining acceptor features of the target pharmacophore.  
GASP 
Rigid Search. Two pairs of ligands were used for rigid searches. The first pair consisted of 
7tln and 1hyt, with 7tln held rigid. The top ranking hypothesis consists of the acceptor A1; 
one of the acceptors to Zn+ (M); and the acceptor A2. The hydrophode H was not deduced 
due to the restricted definition of hydrophobicity used in GASP however this feature can be 
deduced by the user from the alignment. 
The second pair consists of 4tmn and 5tmn with 4tmn held rigid. The best hypothesis is the 
top ranking hypothesis and consists of the features M; A1; H; D1, D2 and A3. The missing 
feature A2 was not found since the NH groups of the ligands point in slightly different 
directions. The hypothesis includes six additional acceptors arising from the carbonyl and 
carboxyl groups that are aligned. 
Flex. Search. The data set was divided into the four subsets as shown in Table 26. The best 
solution for Set 1 is at rank 4 (the first three overlays have the A1 feature of 1hyt aligned with 
the M feature of 7tln and vice versa). The overlay is very similar to that found for the Rigid 
Search using the same pair of ligands with the exception that the NO acceptor now 
corresponds to the correct carboxyl acceptor feature (even if the orientations are not correct). 
The features identified are M (although the hydrogen bonds in the two ligands do not point in 
the same direction), A1 (although the carbonyl group corresponding to this feature is shown 
as forming two H bonds), and A2. The hydrophobe can be deduced from the overlay, as for 
the Rigid Search. The hypothesis includes one additional acceptor arising from the carbonyl 
that corresponds to A1 given as forming two hydrogen bonds. 
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The best hypothesis for Set 2 was at rank two. The features found are M (only one of the two 
interactions is shown), A1, H, D1, D2 and A3. The missing features A2 and one of the bonds 
to Zn+ were not deduced since GASP does not recognise S atoms as being capable of 
binding. Three additional acceptors were found due to the carbonyl groups all being deduced 
as having four acceptors. The top ranking hypothesis is missing feature A3. 
The best hypothesis for Set 3 is at rank three. The features found are M, A1, H, A2, D1, D2 
and A3.  The best solution for Set 4 is at rank three. The features identified are D1, A1, D2 
and A3. M is partially identified since one acceptor is shown and the hydrophobe can be 
deduced from the overlay, as before. 
Combining the four overlays, the pharmacophore can be deduced as consisting of M, A1 and 
H. In addition, another acceptor could be considered to be involved in binding since three of 
the overlays have this extra feature near to the hydrophobe region which could correspond to 
A2 for Sets 1 and 3. By considering Sets 2, 3 and 4 the following features can also be 
deduced: D1, D2, and A3. Again, extra features can be deduced since both Sets 2 and 3 have 
extra features associated with them (three acceptors and one donor and five acceptors 
respectively).  Most likely two to three extra acceptors would be deduced as three of the five 
extra acceptors in Set 3 are due to the carboxyl group at the terminal end of the ligands, 
whereas in Set 2 they are spread along the bulk of the ligands. 
DISCO 
Rigid Search. DISCO generated two models using 5tln as the reference structure. The first 
model consists of a hydrophobe; two donors; two acceptors; and a donor site. Two ligands, 
1hyt and 7tln, have been excluded from the model. Although the features deduced are correct 
(in that all the features shown in the model are present in the binding site), the model does not 
represent how the ligands bind to thermolysin with respect to each other (i.e. the 
pharmacophoric points deduced for one ligand do not necessarily correspond to the same 
features in another ligand). Table 27 shows which features are represented by 
pharmacophoric points in the model, with each column corresponding to the same 
pharmacophoric point of the model. It can be deduced that the model represents the following 
features: H; D1; and either M or A2; with A1 possibly being deduced. The second model is of 
similar quality to the first and hence has not been included in Table 24. 
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Flex Search. The number of conformations produced for each ligand is shown in Table 25. 
Initial attempts, where the requirement was that all the ligands had to fit the model, gave poor 
results. This can be attributed to the two ligands that were excluded from the models 
generated using the bound conformations, they are both small oxygen-rich molecules. Since 
DISCO has to fit all the ligands to every feature of the model generated, it produces models 
that consist of one hydrophobe and three or four acceptors. 
When DISCO was allowed to exclude two ligands from the models (without specifying 
which should be excluded), ligands 7tln and 1hyt were excluded and the resulting models 
were of a better quality. A total of 293 models were obtained organised in 127 groups. In all, 
36 groups have the correct features assigned to the atoms of the reference structure. The two 
best models are at ranks 145 and 254. The highest ranking of these models consists of 
features H, D1 and D2. A1 has been correctly identified for two of the ligands, however, in 
4tmn acceptor A4 is identified in place of A1, and donor D3 is identified in place of D2, and 
in 5tmn acceptor A3 is identified as A1, donor D1 is identified in place of D2 and donor D2 
is identified in place of D2. Thus there are a total of five misses. The second best model 
consists of features H; A1; and D2 although in the case of 4tmn it is actually acceptor A3 that 
is identified and not A1; and donor D2 rather than donor D1 and hence two misses are 
recorded. 
Summary. The order of performance is given as GASP > Catalyst > DISCO. GASP is ranked 
first since it identifies the most features; Catalyst is ranked second because the best 
pharmacophore generated is closer to the target pharmacophore than that generated by 
DISCO, all of the features in the model represent the same features in the ligands (i.e. it has 
fewer misses). The relatively poor performance of DISCO is most likely due to the fact that it 
does not take account of steric overlap. This can lead to incorrect models when there are 
different sets of features at similar distances. Having the ability to take account of steric 
overlap could prevent incorrect assignments to features by ensuring that the scaffold of the 
molecules are used during the alignment. The best hypothesis generated by each of the 
programs is illustrated in Figure 6. 
Conclusions 
The ability of three different commercially available software packages, Catalyst, DISCO and 
GASP, to reproduce known pharmacophores was evaluated and compared. Five different data 
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sets were investigated, including Thrombin, CDK2, DFHR, HIV-RT and Thermolysin. The 
choice of these data sets was dictated by the abundance of crystallographic information, with 
ligands spanning different chemical classes and different properties, from small molecules to 
large, rigid to flexible, feature-poor to feature-rich. Target pharmacophores were defined 
from a visual analysis of the available crystallographic data to contain those features shared 
by all the ligands bound to the same protein. The pharmacophoric features considered include 
hydrogen-bond acceptors and donors, positive and negative charged groups and hydrophobic 
centres. 
Two main sets of experiments were undertaken. The first, or RigidSearch, used only the 
bound structure of each ligand in the pharmacophore derivation process. This experiment 
provided a comparison of the ability of the different programs to identify and match common 
pharmacophoric features. The second, or FlexSearch experiment, allowed all the ligands to 
explore their conformational space. This experiment represented a more real-life situation and 
provided an indication of how each program was able to cope with the more typical 
pharmacophore determination problem. As described in the methods section, the three 
programs use different protocols to explore conformational flexibility. The default protocols 
were used in each case and no attempt was undertaken to either compare the quality of the 
conformations produced or use conformations generated elsewhere (both Catalyst and 
DISCO offer this as an option). 
The results were qualitatively evaluated by visual inspection of the pharmacophore models 
and the alignments obtained. In an attempt to provide a more quantitative comparison we also 
considered whether the target pharmacophore was generated or missed (either partially or 
entirely), and, when generated, its RMS deviation was measured and its rank position in the 
set of solutions produced was recorded. 
One result clearly stands out from this comparative study, which is that GASP and Catalyst 
outperformed DISCO at reproducing the five target pharmacophores. In some cases GASP 
ranked first (CDK2, DHFR and Thermolysin), in other cases Catalyst delivered the best 
results (Thrombin and HIV-RT). In each of the five data sets DISCO consistently performed 
the worst, giving satisfactory results with just two of the datasets (CDK2 and HIV-RT). It is 
noteworthy that, in both these cases, the target pharmacophore consists of three or fewer 
features. 
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Moreover, as DISCO gave low quality results in both the RigidSearch and FlexSearch 
experiments we suggest that these results are not a consequence of inadequate conformational 
searching, but that they are more likely due to the way in which DISCO matches 
pharmacophoric features. As mentioned in the methods section, the main difference between 
DISCO and Catalyst or GASP is in that the former only uses distances between features to 
superimpose ligands. This might be reason for its poorer performance, especially when 
dealing with complex target pharmacophores [53]. 
Catalyst and GASP provided almost equivalent performance even though their results were 
not consistent for all the data sets. A very notable result is that, for both programs, the target 
pharmacophores were found within the first ten solutions in four out of five data sets. It is 
also encouraging that these results were obtained on data sets of very different nature, and 
thus it is tempting to say that they might have general validity. 
It is difficult to clearly differentiate between GASP and Catalyst; both programs have their 
own strengths and weaknesses. 
GASP is inherently simpler than Catalyst and its interface with Sybyl means that many 
operations can be automated through SPL (Sybyl Programming Language). This, for 
instance, makes the visual analysis of the alignments less work-intensive. However, GASP 
requires more work in the input phase. Indeed, for GASP to be effective it often requires the 
dataset to be split into subsets of two or three ligands. This is a direct consequence of the fact 
that in GASP all ligands must match all the pharmacophore model features. The choice of 
subsets can bias the resulting pharmacophores towards preconceived ideas. 
Catalyst provides much more flexibility in setting and tuning the input parameters. It does not 
require that all the ligands match all the features, and the user can specify possible outliers. 
The user also has the possibility of indicating one or multiple reference molecules. However, 
the analysis of the pharmacophore models and the alignments produced can be a painful 
experience due to the cumbersome graphical interface. 
Perhaps the biggest advantage of Catalyst over GASP is that pharmacophoric features can be 
customised and the time invested in modifying current features or introducing new more 
suitable ones is generally reflected in the quality of the models produced. This was found to 
be important in our studies as the restricted definitions of hydrophobic groups and hydrogen-
 26
bond acceptors in GASP resulted in features being missed or having often to be deduced by 
the user.  
GASP's biggest strength over Catalyst is that the former considers not only the 
pharmacophoric features but also the steric overlap of the ligands when deriving a 
pharmacophore model. As a consequence, most of the alignments produced by GASP during 
an experiment tend to be sensible. Catalyst, instead, does not incorporate the steric overlap 
and this is directly reflected in the large proportion of uninteresting alignments that are 
generated.  
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Figure Captions 
Figure 1. Schematic of the best hypothesis generated by Catalyst for the Thrombin data set. 
The corresponding pharmacophore created manually from the bound confomration of 1c4v is 
also shown for comparsion. 
Figure 2. The best hypotheses for Thrombin: Manually generated pharmacophore that 
represents the target pharmacophore (top left); the best hypothesis generated for Catalyst (top 
right); GASP (bottom left); and DISCO (bottom right). 
Figure 3. The best hypotheses for CDK2: Manually generated pharmacophore that represents 
the target pharmacophore (top left); the best hypothesis generated for Catalyst (top right); 
GASP (bottom left); and DISCO (bottom right). 
Figure 4. The best hypotheses for DHFR: Manually generated pharmacophore that represents 
the target pharmacophore (top left); the best hypothesis generated for Catalyst (top right); 
GASP (bottom left); and DISCO (bottom right). 
Figure 5. The best hypotheses for HIV-RT: Manually generated pharmacophore that 
represents the target pharmacophore (top left); the best hypothesis generated for Catalyst (top 
right); GASP (bottom left); and DISCO (bottom right). 
Figure 6. The best hypotheses for Thermolysin: Manually generated pharmacophore that 
represents the target pharmacophore (top left); the best hypothesis generated for Catalyst (top 
right); GASP (bottom left); and DISCO (bottom right). 
 
 
 
Protein Family Number of Ligands
Thrombin 7 
Cyclin Dependent Kinase 2 (CDK2) 6 
 32
Dihydrofolate Reductase (DHFR) 6 
HIV-1 Reverse Transcriptase (HIV-RT) 10 
Thermolysin 6 
Table 1. The protein families used in the comparison. 
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Table 2. The thrombin ligands. 
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 Ligand Feature Code Interaction 
Urea B Basic interaction to ASP189 
Cyclohexyl ring H1 Hydrophobic interaction with  
NH D1 Donor interaction to SER214 
Aliphatic ring H2 Hydrophobic interaction to TRP60D, TYR60A and HIS57 
Carbonyl A1 Acceptor interaction to GLY216 
Phenyl ring H3 Hydrophobic interaction between LEU99 and ILE174 
Table 3. The key interactions involved in binding to Thrombin are described using ligand 
1c4v as reference. 
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  B H1 D1 H2 A1 H3 Target Fit Misses Rank 
Catalyst 
Rigid 
 u     
Catalyst 
Rigid 
u  u
Catalyst 
Flexible 
D u  2 2 
GASP 
Rigid 
D u u 
GASP 
Flex 1 
u u u u u 
GASP 
Flex 2 
A u  u  
GASP 
Flex 3 
D u u 
DISCO 
Rigid 1 
D/A  X 
DISCO 
Rigid 2 
D/A  X 
DISCO 
Rigid 3 
D/A  X 
DISCO 
Flex 
D/A X 
Table 4. Thrombin results. The target pharmacophore consists of B, H1, H2 and H3 marked 
in bold. The GASP subsets are given in Table 5. The details for the DISCO runs are given in 
the text. 
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 Ligand No. Conformers: 
Catalyst 
No. Conformers:
DISCO 
1d6w 174 80 
1fpc 252 80 
1c4v 176 80 
1tom 147 80 
1d4p 100 80 
1d91 173 80 
1dwd 238 80 
Table 5. Number of conformers generated for the thrombin data set by Catalyst (max 255 per 
ligand) and DISCO (max 80 per ligand). 
 
Subset Ligands 
1 1tom; 1dw6; 1c4v; 1fpc 
2 1d9i; 1dwd; 1d4p 
3 1d9i; 1dwd 
Table 6. GASP subsets. 
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Table 7. The CDK2 data set. 
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 Interaction Code  
N D1 Donor interaction to GLU81 
O A1/D2 Acceptor interaction to LEU83  
N D2 Donor interaction to LEU83 
Aromatic ring H1 Hydrophobic interaction to VAL18, AlA31 and LEU134 
Ligands 1di8 and 1fvv D3 Donor interaction to ASP145 
Table 8. The key interactions involved in binding to CDK2 are described using ligand 1aq1 
as reference. 
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  D1 A1 D2 H1 D3 Target Fit Misses Rank
Catalyst 
Rigid 
     1.331 4a - 
Catalyst 
Flex 
 
GASP 
Rigid 
 
GASP 
Flex 1 
 
GASP 
Flex 2 
 
GASP 
Flex 3 
 
GASP 
Flex 4 
x 
DISCO 
Rigid 
 
DISCO 
Flex 
Table 9. The CDK2 results. The target pharmacophore consists of A1 and D1 marked in bold. 
The GASP subsets are given in Table 10. The details for the DISCO runs are given in the 
text. a1fin does not match the pharmacophore. 
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 Ligand No. Conformers: 
Catalyst 
No. Conformers:
DISCO 
1aq1 13 80 
1di8 22 11 
1e1v 62 80 
1e1x 123 80 
1fin 250 80 
1fvv 70 80 
Table 10. Number of conformers generated for the CDK2 data set by Catalyst (max 255 per 
ligand) and DISCO (max 80 per ligand). 
 
Subset Ligands 
1 1elv; 1e1x; 1fvv 
2 1aq1; 1fin 
3 1di8; 1aq1; 1fin 
4 1di8; 1fvv 
Table 11. GASP subsets. 
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Table 12. The DHFR data set. 
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 Interaction Code  
NH2 D1 Donor to GLU30 
N A1 Acceptor to GLU30 
NH2 D2 Donors to ILE7 
NH2 D3 Donors to VAL115 
Pteridine ring H1 Hydrophobic to ILE7, VAL115 and PHE34 
Phenyl ring H2 Hydrophobic to PHE34, PHE31 and ILE60 
Carbonyl A2 Acceptor to ASN64 
Carboxylic acid A3 Acceptor to ARG70 
Carboxylic acid D4 Donor to ARG70 
Table 13. The key interactions involved in binding to DHFR are described based on ligand 
1ohk as reference. 
 43
  D1 A1 D2 D3 H1 H2 A2 A3 D4 Target Fit Misses Rank
Catalyst 
Rigid 
u  
Catalyst 
Flex 1 
X 
Catalyst 
Flex 2 
X 
GASP 
Rigid 
GASP 
Flex 1 
u 
GASP 
Flex 2 
GASP 
Flex 3 
DISCO 
Rigid 1 
DISCO 
Rigid 2 
DISCO 
Flex 1 
DISCO 
Flex 2 
Table 14. The DHFR results. The target pharmacophore consists of D1, A1, H1 and H2 
marked in bold. The GASP subsets are given in Table 16. The details for the DISCO runs are 
given in the text.  
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 Ligand No. Conformers: 
Catalyst 
No. Conformers:
DISCO 
1boz 112 14 
1drl 238 19 
1ohk 217 80 
1dlr 16 80 
1hfp 255 80 
2dhf 206 80 
Table 15. Number of conformers generated for the DHFR data set by Catalyst (max 255 per 
ligand) and DISCO (max 80 per ligand). 
 
Subset Ligands 
1 1drf; 2dhf 
2 1hfp; 1ohk 
3 1boz; 1dlr 
Table 16. GASP subsets. 
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Table 17. The HIV RT data set. 
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 Interaction Code  
NHa D Donor to LYS103 or LYS101 
C=Oa A Acceptor to LYS103 or LYS101 
Large hydrophobic 
region 
H Hydrophobic interaction with TYR188; TYR181; RP229; 
PHE227; LEU100; LEU234; VAL106; TYR318 
Table 18. The key interactions involved in binding to HIV-RT are described based on ligand 
1klm as reference. a the donor/acceptor interactions in 1ep4 and 1klm are to LYS103 whereas 
the other ligands have identical interactions to LYS101. The ligands generally have a 
butterfly shape with the two wings collectively making up the hydrophobic region H. 
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  D A H Target Fit Misses Rank
Catalyst Rigid  
Catalyst Flex 1 X
Catalyst Flex 2 
GASP Rigid 1  
GASP Rigid 2  
GASP Flex  3 u  
GASP Flex  4 
GASP Flex  5 
GASP Flex  6 
GASP Flex  7 
DISCO Rigid  
DISCO Flex 1 
DISCO Flex 2 u 
DISCO Flex 3 
DISCO Flex 4 X 
DISCO Flex 5 
Table 19. HIV-RT results. The target pharmacophore consists of H marked in bold. The 
GASP subsets are given in Tables 21a and 21b. The details for the DISCO runs are given in 
the text. 
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  No conformers: 
Catalyst 
No conformers:
DISCO 
1fk9 
1vru 
1rt3 
1bqm 
1tvr 
1rt1 
1rt5 
1klm 
1ep4 
1dtt 
Table 20. No. of conformers generated for the HIV-RT data set by Catalyst (max 255 per 
ligand) and DISCO (max 100 per ligand). 
 
Subset Ligands 
1 1dtt, 1klm, 1rt5  
2 1fk9, 1bqm, 1klm 
Table 21a. GASP subsets used in the Rigid Searches. 
 
Subset Ligands 
3 1bqm, 1fk9, 1klm 
4 1dtt, 1rt5 
5 1rt3, 1vru 
6 1ep4, 1klm 
7 1tvr, 1rt1 
Table 21b. GASP subsets used in the Flex Searches. 
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Table 22. Thermolysin data set. 
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Interaction Code  
Bidentate chelation with Zn+ 
(O or S) 
M  
C=O H-bond acceptor A1 H-bond with ARG203 
Hydrophobe H Hydrophobic interaction with LEU133;  VAL139;  
ILE188;  LEU202 
Oxygen H-bond acceptor A2 H-bond with GLU143 
N-H H-bond donor D1 H-bond with ALA113 
N-H H-bond donor D2 H-bond with ASN112 
C=O H-bond acceptor A3 H-bond with ASN112 
N-H H-bond donor D3 H-Bond with TYR157 
C=O H-bond acceptor A4 H-bond with TRP115 
Table 23. The key interactions involved in binding to Thermolysin are described based on 
ligand 4tmn as reference. 
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  M A1 H A2 D1 D2 A3 D3 A4 Target Fit1 Misses1 Rank
Catalyst 
Rigid 
X
Catalyst 
Flex 
X 
GASP 
Rigid 
P u 
GASP 
Rigid 
X 
GASP 
Flex 1 
u 
GASP 
Flex 2 
P X 
GASP 
Flex 3 
GASP 
Flex 4 
P u X
DISCO 
Rigid 
DISCO 
Flex 1 
X 
DISCO 
Flex 2 
X 
Table 24. Thermolysin results. The target pharmacophore consists of M, A1, H, and A2 
marked in bold. The GASP subsets are given in Table 26. The details for the DISCO runs are 
given in the text. P = Partially found (i.e. found 1 or 2 features); ?? = one of the two features 
could be deduced from the model  one atom has both interactions. 
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Ligand No. Conformers: 
Catalyst 
No. Conformers:
DISCO 
1hyt 74 100
1qf1 221 100
4tmn 255 100 
5tln 250 100
5tmn 253 100 
7tln 18 100
Table 25. Number of conformers generated for the Thermolysin data set by Catalyst (max 
255 per ligand) and DISCO (max 100 per ligand). 
Subset Ligands 
1 7tln, 1hyt 
2 1qf1, 5tln 
3 4tmn, 5tln 
4 1qf1, 5tmn 
Table 26. GASP subsets. 
Ligand Hydrophobe Acceptor 
Atom 
Donor 
Atom 
Acceptor Atom and 
Donor Site 
Donor 
Atom 
5tln H A1 D2 A3 - 
1qf1 H A1 D1 M M or A2 
4tmn H A4 D3 M or A2 D1 
5tmn H - - M or A2 D1 
Table 27. Correspondences between ligand features and the features in the hypothesis 
generated by DISCO. 
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Bond Angles:
1-2-3:   128.5o.
2-3-4:   102.2o.
3-4-5:   53.6o.
4-5-1:   146.6o.
5-1-2:   15.39o.
Torsion Angles:
1-2-3-4:   -150.1o.
2-3-4-5:   10.6o.
3-4-5-1:   14.5o.
4-5-1-2:   -50.8o.
5-1-2-3:   114.9o.
5.12 Å
8.73 Å
B (1)
11.70 Å
H3 (4)
H2 (3)
D1 (coming out of the 
plane of the paper) (2)
A1 (5)
7.80 Å
6.07 Å16.19 Å
10.11 Å
6.76 Å
3.32 Å 5.82 Å
11.50 Å
6.34 Å
3.44 Å5.66 Å
H3 (4)
H2 (3)
D1 (coming out of the 
plane of the paper) (2)
A1 (5)
B (1) 5.47 Å
11.76 Å
6.54 Å
8.89 Å
6.52 Å
7.30 Å
Bond Angles:
1-2-3:   153.6o.
2-3-4:   86.6o.
3-4-5:   55.8o.
4-5-1:   148.8o.
5-1-2:   32.7o.
Torsion Angles:
1-2-3-4:   -18.8o.
2-3-4-5:   8.7o.
3-4-5-1:   -165.0o.
4-5-1-2:   153.7o.
5-1-2-3:   5.7o.
Figure 1. 
Figure 2. 
Figure 3. 
Figure 4. 
Figure 5. 
Figure 6 
Appendix 
Parameter Value
No. of Overlays 15 
Popsize 100
Select Pressure 1.1 
Niche Size 2 
Max_ops 60000
Ops_inc 6500
Fit_inc 0.01
N_islands 5
Migrate 10
Mutate 95
Pt_cross 95
Do Volume Overlap selected 
Internal Energy Weight 0.05 
Pharmacophore Creation Weight 750.0 
Table A1. Parameter settings used for GASP Flex Searches. 
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Parameter Value 
Max No. Conformers 255 
E-range 20 (Kcal of min) 
SuperpositionError 1 
ToleranceFactor 1 
CheckSuperposition 1 
WeightVariation 0.302 
MappingCoeff 0 
IdealHBondGeomOnly 0 
VariableWeight 0 
VariableTolerance 0 
MaxOmitFeat column in report All ligands given a value of 2 
Hydrophobe 0-5 
HB-acceptor 0-5 
HB-donor 0-5 
Pos. Ionisable 0-5 
Neg. Ionisable 0-5 
Max. No. of Features 10 
Table A2. Data set independent parameter settings used for Flex Searches in Catalyst. 
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Parameter Thrombin  CDK2  DHFR  Hiv-RT  Thermolysin  
HyposReported 120 100 100 120 120 
Spacing 297 297 297 190 220 
MinPoints 2 2 2 2 3 
MinSubsetPoints 2 2 2 1 2 
Misses 4 1 1 3 3 
FeatureMisses 4 1 1 3 3 
CompleteMisses 0 0 0 2 2 
Mem 120 120 120 60 120 
MaxOmitFeat coloumn  
in report 
All ligands: 2 All ligands: 0 All ligands: 0 All ligands  All ligands:  
Principal compound  
column in report 
All ligands: 2 All ligands: 2 All ligands: 2 All ligands: 2  All ligands:  
2 except  
7tln (=1) and 
1hyt (=1)   
Table A3. Data set specific parameters used for Flex Searches in Catalyst. 
 
Prescreening: Conformer Comparison: 
Minimizer = maximin criteria = Max Distance 
Energy Cutoff = 70 Deviation Limit = 0.40 
Maximin RMS Gradient = 3  
Table A4. Conformational analysis parameters used in DISCO runs. 
 
Thrombin,  CDK2: Hiv-RT,  Thermolysin,  DHFR: 
Maximum Cycles = 1500 Maximum Cycles = 1500 
Max Conformers = 80 Max Conformers = 100 
Hit Limit = 150 Hit Limit = 150 
Table A5. Termination parameters used in DISCO runs. 
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Parameter Thrombin  CDK2  DHFR HIV-RT Thermolysin 
Reference  
Structure 
1d4p (default) 1e1x 1ohk 1fk9 5tln 
Structure  
Requirements 
2 Mismatches 
Allowed 
2 Mismatches 
Allowed 
2 Mismatches 
Allowed 
4 Mismatches 
Allowed 
2 Mismatches 
Allowed 
Feature  
Requirements 
Do 3 to 8 
(default) 
Do 3 to 8 
(default) 
Do 3 to 8 
(default) 
Do 3 to 8 
(default) 
Must Contain: 
1 Hydrophobe 
All other  
features 
left open 
Distance  
Tolerances 
Coarse Fit 
(Default) 
Coarse Fit 
(Default) 
Coarse Fit 
(Default) 
Coarse Fit 
(Default) 
Coarse Fit 
(Default) 
Energy Limit 20.00 20.00 20.00 20.00 20.00 
Table A6. Parameter settings used for DISCO Flex Searches. 
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